[Clinical use of platinum compounds and fluorinated pyrimidines for lung cancer].
In this review, the clinical uses of a new platinum compound, nedaplatin, and a new oral fluoropyrimidine, S-1, for lung cancer are described. The clinical application of biochemical modulation of 5-fluorouracil by cisplatin is also reviewed.
Kobayashi
K
K
Fourth Dept. of Internal Medicine, Nippon Medical School, Tokyo, Japan.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002945:Cisplatin / Q000627:therapeutic use*; D004338:Drug Combinations; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000627:therapeutic use; D014498:Uracil / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; C053194:Emitefur; D016190:Carboplatin; D002945:Cisplatin; D005472:Fluorouracil